Department of Cardiology, Konkuk University School of Medicine, Chungju Hospital, Chungju, Korea.
Korean Circ J. 2011 Sep;41(9):546-8. doi: 10.4070/kcj.2011.41.9.546. Epub 2011 Sep 29.
Stroke is a rare but serious complication of acute myocardial infarction (AMI). Currently, glycoprotein (GP) IIb/IIIa inhibitor is used in clinical practice for acute coronary syndromes and percutaneous coronary interventions (PCIs). The incidence of stroke in patients receiving GP IIb/IIIa inhibitor during PCIs is very low. We report the case of a 47-year-old man who presented with AMI and suffered an acute cerebral infarction after infusion of a GP IIb/IIIa inhibitor following primary PCI.
中风是急性心肌梗死(AMI)的罕见但严重的并发症。目前,糖蛋白(GP)IIb/IIIa 抑制剂在急性冠脉综合征和经皮冠状动脉介入治疗(PCIs)中用于临床。在接受 GP IIb/IIIa 抑制剂治疗的 PCI 患者中,中风的发生率非常低。我们报告了一例 47 岁男性患者,他因 AMI 就诊,在初次 PCI 后输注 GP IIb/IIIa 抑制剂后发生急性脑梗死。